Anticancer drugs: Breaking up a pro-survival interaction
Nature Reviews Cancer 16, 754 (2016).
doi:10.1038/nrc.2016.139
Author: Alexandra Flemming
A paper in Nature describes a highly specific and potent small molecule inhibitor of MCL1 that has single-agent activity and good tolerability in several cancer models.
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Alexandra Flemming Tags: Research Highlight Source Type: research
More News: Cancer | Cancer & Oncology